TSXV:CLAS.H - Post by User
Post by
JamesNeven1983on Feb 05, 2020 9:31am
59 Views
Post# 30645151
Great news
Great newsKalytera has exclusive worldwide rights to the use of CBD in the prevention and treatment of GVHD under two U.S. patents that were issued in 2018, as well as this new U.S. patent and the EU patent that is expected to be granted later this month. Kalytera has also obtained four orphan drug designations for the treatment and prevention of GVHD in the U.S. and Europe. In addition to protection from competition granted to the Company under its patents, the U.S. and EU orphan drug designations will provide 7 years of market exclusivity in the U.S., and 10 years of market exclusivity in the E.U., upon regulatory approval of the Companys CBD products for the prevention and/or treatment of GVHD.